Patents by Inventor Caroline Leriche

Caroline Leriche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aniline derivatives, their preparation and their therapeutic application
    Patent number: 9624159
    Abstract: The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: April 18, 2017
    Assignee: SANOFI
    Inventors: John Feutrill, Caroline Leriche, David Middlemiss
  • ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
    Publication number: 20160199330
    Abstract: The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Application
    Filed: December 14, 2015
    Publication date: July 14, 2016
    Inventors: John FEUTRILL, Caroline LERICHE, David MIDDLEMISS
  • Aniline derivatives, their preparation and their therapeutic application
    Patent number: 9249085
    Abstract: The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: February 2, 2016
    Assignee: FOVEA PHARMACEUTICALS
    Inventors: John Feutrill, Caroline Leriche, David Middlemiss
  • ANILINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
    Publication number: 20140350019
    Abstract: The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 27, 2014
    Applicant: FOVEA PHARMACEUTICALS
    Inventors: John Feutrill, Caroline Leriche, David Middlemiss
  • Diazepane acetamide derivatives as selective 11B-HSD1 inhibitors
    Patent number: 8586577
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: November 19, 2013
    Assignee: Merck Patent GmbH
    Inventors: Denis Carniato, Caroline Leriche, Didier Roche, Christine Charon, Liliane Doare
  • NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1
    Patent number: 8546575
    Abstract: The present invention relates to NIP thiazole derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: October 1, 2013
    Assignee: Merck Patent GmbH
    Inventors: Caroline Leriche, Denis Carniato, Didier Roche, Christine Charon, Liliane Doare
  • HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION
    Publication number: 20130123271
    Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder.
    Type: Application
    Filed: June 22, 2011
    Publication date: May 16, 2013
    Applicant: FOVEA PHARMACEUTICALS
    Inventors: David Middlemiss, Caroline Leriche
  • Substituted quinazoline compounds
    Patent number: 8389530
    Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: March 5, 2013
    Assignee: Fovea Pharmaceuticals
    Inventors: Caroline Leriche, Eric Auclair, Jacques Le Roux, David N. Middlemiss
  • DIAZEPANE ACETAMIDE DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS
    Publication number: 20120283247
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 8, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Denis CARNIATO, Caroline LERICHE, Didier ROCHE, Christine CHARON, Liliane DOARE
  • Diazepane-acetamide derivatives as selective 11?-HSD1 inhibitors
    Patent number: 8242107
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: August 14, 2012
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Denis Carniato, Caroline Leriche, Didier Roche, Christine Charon, Liliane Doare
  • Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
    Patent number: 8232272
    Abstract: The present invention relates to novel benzimidazole-dihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, to processes for the preparation thereof and to the use thereof in therapy, especially for the treatment of diabetes.
    Type: Grant
    Filed: October 13, 2008
    Date of Patent: July 31, 2012
    Assignee: Merck Patent Gesellschaft mit beschränkter Haftung
    Inventors: Gerard Botton, Caroline Leriche, Annick Arbellot de Vacqueur, Annick Audet, Johannes Gleitz
  • 2-adamantyl-butyramide derivatives as selective 11?-HSD1 inhibitors
    Patent number: 8183265
    Abstract: The present invention relates to 2-adamantyl-butyramide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: November 22, 2007
    Date of Patent: May 22, 2012
    Assignee: Merck Patent GmbH
    Inventors: Didier Roche, Denis Carniato, Liliane Doare, Christine Charon, Caroline Leriche
  • Heterocyclic compounds
    Publication number: 20120041195
    Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted triazolopyridine compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder. In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.
    Type: Application
    Filed: February 9, 2010
    Publication date: February 16, 2012
    Inventors: Caroline Leriche, Eric Auclair, Jacques Le Roux, David Middlemiss
  • SUBSTITUTED QUINAZOLINE COMPOUNDS
    Publication number: 20120004210
    Abstract: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder, In particular, the methods relate to treating or ameliorating a kinase-mediated disorder including cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, cancer and diseases of the eye such as retinopathies or macular degeneration or other vitreoretinal diseases, and the like.
    Type: Application
    Filed: December 18, 2009
    Publication date: January 5, 2012
    Inventors: Caroline Leriche, Eric Auclair, Jacques Le Roux, David Middlemiss
  • Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1
    Publication number: 20110060007
    Abstract: The present invention relates to NIP thiazole derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: April 8, 2009
    Publication date: March 10, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftling
    Inventors: Caroline Leriche, Denis Carniato, Didier Roche, Christine Charon, Liliane Doare
  • NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
    Publication number: 20100286129
    Abstract: The present invention relates to novel benzimidazole-dihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, to processes for the preparation thereof and to the use thereof in therapy, especially for the treatment of diabetes.
    Type: Application
    Filed: October 13, 2008
    Publication date: November 11, 2010
    Inventors: Gerard Botton, Caroline Leriche, Annick Arbellot De Vacqueur, Annick Audet, Johannes Gleitz
  • Diazepane-acetamide derivatives as selective 11B-HSD1 inhibitors
    Publication number: 20100069365
    Abstract: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: October 5, 2007
    Publication date: March 18, 2010
    Applicant: MERCK PATENT GMBH
    Inventors: Denis Carniato, Caroline Leriche, Didier Roche, Christine Charon, Liliane Doare
  • 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS
    Publication number: 20100022597
    Abstract: The present invention relates to 2-adamantyl-butyramide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: November 22, 2007
    Publication date: January 28, 2010
    Inventors: Didier Roche, Denis Carniato, Liliane Doare, Christine Charon, Caroline Leriche
  • Antidiabetic compounds comprising benzofuran and benzothiophene derivatives
    Patent number: 7375130
    Abstract: The invention relates to compounds of the general formula (I) below: in which R1, R2, R3, R4, R5, R6 and X are as defined in claim 1. These compounds can be used in the treatment of pathologies associated with insulin resistance syndrome.
    Type: Grant
    Filed: October 26, 2004
    Date of Patent: May 20, 2008
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Gérard Moinet, Caroline Leriche, Micheline Kergoat
  • Benzofurans and benzothiophenes
    Patent number: 7371774
    Abstract: The invention relates to compounds of the general formula (I) below: in which R1, R2, R3, R4, R5, R6 and X are as defined in claim 1. These compounds can be used in the treatment of pathologies associated with insulin resistance syndrome.
    Type: Grant
    Filed: November 8, 2004
    Date of Patent: May 13, 2008
    Assignee: Merck Patent GmbH
    Inventors: Gérard Moinet, Caroline Leriche, Micheline Kergoat